Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-positive Breast Cancer × 30 days × Clear all

Phase

Phase 3 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 7 Carcinoma, Non-Small-Cell Lung 7 Prostatic Neoplasms 5 Neoplasms 5 Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Lung Neoplasms 4 Myasthenia Gravis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Fallopian Tube Neoplasms 3 Urinary Bladder Neoplasms 2 Recurrence 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Carcinoma 2 Myelodysplastic Syndromes 2 Liposarcoma 2 Leukemia, Myelomonocytic, Chronic 2 Laryngeal Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Adenocarcinoma Of Esophagus 2 Uterine Cervical Neoplasms 1 Ulcer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1

Interventions

tucatinib 1 Trastuzumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡